TY - JOUR T1 - Contribution of TGFβ1 and TIMP2 to clinical activity of asthma and COPD JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - p3907 AU - Navid Abolfath Zade Ghalejooghi AU - Mostafa Ghanei AU - Mohammad Reza Nourani AU - Ali Amini Harandi AU - Abbas Ali Imani Fooladi Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/p3907.abstract N2 - Introduction: The process of bronchial tissue repair and remodeling in airway diseases depends on balance between production and degradation of different cytokines, leading to the regulation of extracellular matrix turnover finally.Objectives: This study was designed to evaluate contribution of Transforming Growth Factor β1 (TGFβ1) and Tissue Inhibitor of Metaloproteinase-2 (TIMP2) to clinical activity and reversibility of asthma and chronic obstructive pulmonary disease (COPD).Methods: In a cross sectional study on two groups of 29 asthmatics (14 males and 15 females) and 13 male COPD patients, we evaluated TIMP2 and TGFβ1 expression using semi-quantitative PCR on induced sputum samples. The relation among TIMP2 and TGFβ1 and pulmonary function test (PFT) indices and disease free period were assessed.Results: Higher pulmonary function test (PFT) indices and longer disease free period was seen in COPD patients with raised expression of both TGFβ1 and TIMP2. On the other hand asthmatic patients had better pulmonary function status with raised TIMP2 and decreased TGFβ1 expression (p<0.05).Conclusion: It seems that different effect of cytokines like TGFβ1 and TIMP2 in both diseases is depended on underlying inflammatory process in airways epithelium. We supposed that TGFβ1 bidirectionally affects activity of disease in asthma and COPD. Furthermore TGFβ1 as a biomarker in sputum may have a role for evidence-based drug prescribing like corticosteroids in patients with COPD and asthma. ER -